Given the lack of effective treatments for FLT3-mutated unfit AML patients and the disappointing results of azacitidine alone in this subset of patients [156], FLT3 inhibitors have been tested in combination with HMAs, following the demonstration of their synergistically cytotoxic effect [157]. Here, FLT3 is linked to acute myeloid leukemia.